This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



EfficacyEfficacyKey Take AwaysHospitalisation DataSafetySafetyAdverse Event Management: VOD/SOSSelected Adverse ReactionsDosingDosing and Dose ModificationsAdministrationSupport and ResourcesPublications
AdministrationBefore Administering BESPONSA1UV; ultraviolet.Pre-medication with a corticosteroid, antipyretic, and antihistamine is recommended prior to dosing1
  • For patients with circulating lymphoblasts, cytoreduction with a combination of hydroxyurea, steroids, and/or vincristine to a peripheral blast count ≤ 10,000/mm3 is recommended prior to the first dose1
How to Administer BESPONSA
  • Besponsa must be reconstituted before use. Please refer to the Besponsa Summary of Product Characteristics for the reconstitution steps.
  • The reconstituted solution of BESPONSA must be diluted with sodium chloride 0.9% solution for injection to a nominal value of 50mL, and administered at a flow rate of 50mL/hr at room temperature (20 -25 °C).
During and After Administering BESPONSAObserve patients for ≥ 1 hour post infusion1

Patients should be observed during and for at least 1 hour after the end of the infusion for symptoms of infusion-related reactions1

ALL=acute lymphoblastic leukemia; R/R=relapsed/refractory; RWE=real-world evidence; SmPC=Summary of Product Characteristics.References:BESPONSA Summary of Product Characteristics
Dosing Besponsa Prescribing Information Visit Loading

Legal Category: S1A
Further information is available upon request

PP-INO-IRL-0114 January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0784. June 2024